How long should first-line chemotherapy continue?

被引:7
作者
Bertelsen, K [1 ]
Grenman, S
Rustin, GJS
机构
[1] Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark
[2] Turku Univ, Cent Hosp, Dept Obstet & Gynaecol, Turku, Finland
[3] Mt Vernon Hosp, Dept Med Oncol, Northwood HA6 2RN, Middx, England
关键词
advanced ovarian cancer; chemotherapy; duration; treatment;
D O I
10.1023/A:1008399132535
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Documentation for the optimal duration of first-line chemotherapy in advanced ovarian cancer is limited. Three randomised trials have compared 5-6 cycles with 8, 10 and 12 cycles respectively. None of the studies showed benefit of chemotherapy beyond 6 cycles. At the moment the standard number of cycles therefore must be 6 cycles. However, these data are based on platinum poly-chemotherapy regimens without taxanes. It may be that the optimal number of cycles is different when using taxanes regimens. It is not possible to tell from the literature if there is a relationship between the number of cycles and response or between the cumulative dose and response. At the moment no trial has shown any benefit of high-dose intensity chemotherapy administered over a short time compared with standard dose chemotherapy administered over a longer period.
引用
收藏
页码:17 / 20
页数:4
相关论文
共 14 条
[1]  
ALLEN DG, 1993, ANN ONCOL, V4, P83
[2]   A PROSPECTIVE RANDOMIZED COMPARISON OF 6 AND 12 CYCLES OF CYCLOPHOSPHAMIDE, ADRIAMYCIN, AND CISPLATIN IN ADVANCED EPITHELIAL OVARIAN-CANCER - A DANISH OVARIAN STUDY-GROUP TRIAL (DACOVA) [J].
BERTELSEN, K ;
JAKOBSEN, A ;
STROYER, I ;
NIELSEN, K ;
SANDBERG, E ;
ANDERSEN, JE ;
AHRONS, S ;
NYLAND, M ;
PEDERSEN, PH ;
LARSEN, G ;
RASMUSSEN, P ;
KIAER, H ;
BICHEL, P ;
JACOBSEN, M ;
HOLUND, B .
GYNECOLOGIC ONCOLOGY, 1993, 49 (01) :30-36
[3]   A RANDOMIZED STUDY OF CYCLOPHOSPHAMIDE AND CISPLATINUM WITH OR WITHOUT DOXORUBICIN IN ADVANCED OVARIAN-CARCINOMA [J].
BERTELSEN, K ;
JAKOBSEN, A ;
ANDERSEN, JE ;
AHRONS, S ;
PEDERSEN, PH ;
KIAER, H ;
ARFFMANN, E ;
BICHEL, P ;
BOESTOFTE, E ;
CHRISTOPHERSEN, IS ;
GREGERSEN, E ;
HANSEN, MK ;
HOLUND, B ;
JACOBSEN, M ;
JENSEN, HK ;
JEPSEN, FL ;
LARSEN, G ;
NIELSEN, ES ;
NYLAND, M ;
OLSEN, J ;
PANDURO, J ;
RANK, F ;
SELL, A ;
SOGAARD, H .
GYNECOLOGIC ONCOLOGY, 1987, 28 (02) :161-169
[4]   Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer [J].
Bolis, G ;
Favalli, G ;
Danese, S ;
Zanaboni, F ;
Mangili, G ;
Scarabelli, C ;
Tateo, S ;
Valsecchi, MG ;
Scarfone, G ;
Richiardi, G ;
Frigerio, I ;
Melpignano, M ;
Villa, A ;
Parazzini, F .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :1938-1944
[5]   CHEMOTHERAPY VERSUS RADIOTHERAPY IN THE MANAGEMENT OF OVARIAN-CANCER PATIENTS WITH PATHOLOGICAL COMPLETE RESPONSE OR MINIMAL RESIDUAL DISEASE AT 2ND LOOK [J].
BRUZZONE, M ;
REPETTO, L ;
CHIARA, S ;
CAMPORA, E ;
CONTE, PF ;
ORSATTI, M ;
VITALE, V ;
RUBAGOTTI, A ;
ROSSO, R .
GYNECOLOGIC ONCOLOGY, 1990, 38 (03) :392-395
[6]   RANDOMIZED PROSPECTIVE TRIAL OF 5 VERSUS 10 CYCLES OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN IN ADVANCED OVARIAN-CARCINOMA [J].
HAKES, TB ;
CHALAS, E ;
HOSKINS, WJ ;
JONES, WB ;
MARKMAN, M ;
RUBIN, SC ;
CHAPMAN, D ;
ALMADRONES, L ;
LEWIS, JL .
GYNECOLOGIC ONCOLOGY, 1992, 45 (03) :284-289
[7]   NEOADJUVANT CHEMOTHERAPY AND INTERVAL DEBULKING FOR ADVANCED EPITHELIAL OVARIAN-CANCER [J].
JACOB, JH ;
GERSHENSON, DM ;
MORRIS, M ;
COPELAND, LJ ;
BURKE, TW ;
WHARTON, JT .
GYNECOLOGIC ONCOLOGY, 1991, 42 (02) :146-150
[8]   A RANDOMIZED TRIAL COMPARING SINGLE-AGENT CARBOPLATIN WITH CARBOPLATIN FOLLOWED BY RADIOTHERAPY FOR ADVANCED OVARIAN-CANCER - A NORTH-THAMES-OVARY-GROUP STUDY [J].
LAMBERT, HE ;
RUSTIN, GJS ;
GREGORY, WM ;
NELSTROP, AE .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :440-448
[9]   A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma - A North Thames Ovary Group Study [J].
Lambert, HE ;
Rustin, GJS ;
Gregory, WM ;
Nelstrop, AE .
ANNALS OF ONCOLOGY, 1997, 8 (04) :327-333
[10]   ASSESSMENT OF DOSE-INTENSIVE THERAPY IN SUBOPTIMALLY DEBULKED OVARIAN-CANCER - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY [J].
MCGUIRE, WP ;
HOSKINS, WJ ;
BRADY, MF ;
HOMESLEY, HD ;
CREASMAN, WT ;
BERMAN, ML ;
BALL, H ;
BEREK, JS ;
WOODWARD, J .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) :1589-1599